Medifast (NYSE:MED) Share Price Crosses Above 200-Day Moving Average – What’s Next?

Shares of Medifast Inc (NYSE:MED) passed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $11.23 and traded as high as $11.57. Medifast shares last traded at $11.0690, with a volume of 344,977 shares trading hands.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on MED. Wall Street Zen raised shares of Medifast from a “sell” rating to a “hold” rating in a report on Saturday, March 21st. Weiss Ratings downgraded shares of Medifast from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, May 6th. One investment analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Reduce” and an average price target of $12.00.

Medifast Stock Performance

The business has a 50 day simple moving average of $11.85 and a two-hundred day simple moving average of $11.22. The firm has a market capitalization of $115.31 million, a P/E ratio of -5.67 and a beta of 0.62.

Medifast (NYSE:MED) last issued its quarterly earnings results on Monday, May 4th. The specialty retailer reported ($0.19) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.36. Medifast had a negative return on equity of 4.80% and a negative net margin of 5.78%.The firm had revenue of $76.04 million during the quarter, compared to the consensus estimate of $69.20 million. Medifast has set its FY 2026 guidance at -2.750–1.550 EPS and its Q2 2026 guidance at -1.000–0.500 EPS. On average, equities analysts anticipate that Medifast Inc will post -1.97 earnings per share for the current fiscal year.

Insider Transactions at Medifast

In related news, Director Scott Schlackman purchased 2,500 shares of the business’s stock in a transaction on Monday, May 11th. The stock was acquired at an average price of $12.53 per share, with a total value of $31,325.00. Following the purchase, the director directly owned 30,549 shares in the company, valued at approximately $382,778.97. This represents a 8.91% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 3.70% of the stock is currently owned by insiders.

Institutional Trading of Medifast

Several institutional investors and hedge funds have recently made changes to their positions in MED. State of Wyoming grew its position in Medifast by 19.8% in the first quarter. State of Wyoming now owns 6,646 shares of the specialty retailer’s stock worth $68,000 after acquiring an additional 1,097 shares in the last quarter. BNP Paribas Financial Markets raised its position in Medifast by 103.1% during the third quarter. BNP Paribas Financial Markets now owns 2,338 shares of the specialty retailer’s stock valued at $32,000 after purchasing an additional 1,187 shares in the last quarter. Man Group plc raised its position in Medifast by 0.6% during the second quarter. Man Group plc now owns 198,156 shares of the specialty retailer’s stock valued at $2,784,000 after purchasing an additional 1,200 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in Medifast by 2.5% during the second quarter. JPMorgan Chase & Co. now owns 53,341 shares of the specialty retailer’s stock worth $749,000 after purchasing an additional 1,316 shares during the last quarter. Finally, Barclays PLC lifted its stake in Medifast by 10.6% during the fourth quarter. Barclays PLC now owns 16,769 shares of the specialty retailer’s stock worth $179,000 after purchasing an additional 1,608 shares during the last quarter. Hedge funds and other institutional investors own 95.51% of the company’s stock.

About Medifast

Medifast, Inc (NYSE: MED) is a health and wellness company specializing in clinically supported weight-loss, weight-management and healthy living products and services. Through its OPTAVIA brand, the company offers a range of meal replacement products, snacks, supplements and coaching programs designed to support metabolic health and sustainable lifestyle changes. Medifast markets its products directly to consumers via a network of independent distributors—known as OPTAVIA Coaches—who provide personalized guidance and support throughout the client’s weight‐loss journey.

Founded in 1980 by William Vitale and headquartered in Baltimore, Maryland, Medifast has grown into a nationally recognized provider of nutrition and weight‐management solutions.